# Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 Canonical URL: https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of--55624eac Ticker: AUTL Company: Autolus Therapeutics plc Source: Autolus Therapeutics plc Published: 2026-05-21 21:10 EST ## Summary Autolus announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting.... ## Article Body Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. “Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients,” said Matthias Will, MD, Autolus Chief Development Officer. Abstract 6517 Title : The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). Session Type and Track: Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Session Date and Time : May 30, 2026; 1:15 – 2:45PM CDT Session Room : E450a Abstract Number : 6517 Presentation time: 2:27 – 2:33pm CDT Presenting Author : Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD. About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com . Contact: Amanda Cray +1 617-967-0207 a.cray@autolus.com ## Recent Company News - 2026-07-01 20:05 EST — [Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c43a8fbe) — Source: Autolus Therapeutics plc - 2026-06-25 11:00 EST — [Autolus Therapeutics to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conference-ec70e012) — Source: Autolus Therapeutics plc - 2026-06-12 08:00 EST — [Autolus Therapeutics Receives Prix Galien UK Award](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-receives-prix-galien-uk-award-395b0660) — Source: Autolus Therapeutics plc - 2026-05-27 11:00 EST — [Autolus Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conferences-1fafa41c) — Source: Autolus Therapeutics plc - 2026-05-21 21:10 EST — [Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of--55624eac) — Source: Autolus Therapeutics plc ## Related News - 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a) - 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a) - 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2) - 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11) - 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)